Nov 18, 2026, 7:30 AM EST · 2 days ago Zevra Therapeutics to Present at the Piper Sandler Annual Healthcare Conference
2026-11-16T12:52:11.000Z · 4 days ago Zevra Therapeutics price target lowered to $18 from $23 at Guggenheim
Nov 13, 2026, 6:26 AM EST · 7 days ago Zevra Therapeutics Announces Final CHMP Opinion on Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union
Nov 3, 2026, 4:05 PM EST · 16 days ago Zevra Reports Third Quarter 2026 Financial Results and Corporate Update
Oct 20, 2026, 7:30 AM EDT · 4 weeks ago Zevra Therapeutics Announces Details for Q3 2026 Financial Results Call
Sep 2, 2026, 7:30 AM EDT · 2 months ago Zevra Therapeutics to Present at Upcoming Investor Conferences
Aug 25, 2026, 7:30 AM EDT · 2 months ago Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium
Aug 21, 2026, 4:30 PM EDT · 3 months ago Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-08-07T11:46:38.000Z · 3 months ago Zevra Therapeutics price target lowered to $23 from $24 at Guggenheim
2026-08-06T09:50:22.000Z · 3 months ago Zevra Therapeutics price target raised to $28 from $25 at Citizens
Aug 5, 2026, 4:05 PM EDT · 3 months ago Zevra Reports Second Quarter 2026 Financial Results and Corporate Update
Aug 4, 2026, 7:30 AM EDT · 3 months ago Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference
Aug 3, 2026, 7:30 AM EDT · 3 months ago Zevra Therapeutics Announces Publication of Four-Year Real-World Data from U.S. Early Access Program Evaluating MIPLYFFA® (arimoclomol) in Niemann-Pick Disease Type C (NPC)
Jul 27, 2026, 8:40 PM EDT · 3 months ago ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law
2026-07-27T12:15:58.000Z · 3 months ago Spruce Biosciences appoints Quartel as Chief Medical Officer SPRB
2026-07-27T11:21:03.000Z · 3 months ago Zevra Therapeutics price target lowered to $24 from $29 at Guggenheim
2026-07-27T11:11:18.000Z · 3 months ago Zevra Therapeutics price target lowered to $24 from $27 at BTIG
2026-07-27T10:45:40.000Z · 3 months ago Zevra Therapeutics price target lowered to $20 from $29 at Canaccord
2026-07-24T15:20:18.000Z · 3 months ago EU opinion ‘headwind, but not insurmountable’ for Zevra, says H.C. Wainwright
2026-07-24T12:25:51.000Z · 3 months ago Zevra Therapeutics down 30% at $8.78 after negative CHMP opinion on arimoclomol
2026-07-24T11:45:45.000Z · 3 months ago Zevra Therapeutics announces negative CHMP opinion on arimoclomol MAA
Jul 24, 2026, 7:30 AM EDT · 3 months ago Zevra Therapeutics Provides Update on Regulatory Submission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union
Jul 22, 2026, 7:30 AM EDT · 4 months ago Zevra Therapeutics Announces Details for Q2 2026 Financial Results Call
2026-06-23T13:33:10.000Z · 5 months ago Zevra publishes Miplyffa data in Molecular Genetics, Metabolism Reports
Jun 23, 2026, 7:30 AM EDT · 5 months ago Zevra Therapeutics Announces Publication of Positive MIPLYFFA® Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC)
Jun 11, 2026, 8:30 AM EDT · 5 months ago Zevra's Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition
2026-06-10T17:36:05.000Z · 5 months ago Zevra Therapeutics price target raised to $35 from $25 at Maxim
2026-06-10T11:21:28.000Z · 5 months ago Zevra Therapeutics price target raised to $29 from $25 at Guggenheim
Jun 8, 2026, 7:30 AM EDT · 5 months ago Zevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFA
May 12, 2026, 7:30 AM EDT · 6 months ago Zevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference
May 6, 2026, 4:05 PM EDT · 6 months ago Zevra Reports First Quarter 2026 Financial Results and Corporate Update
Mar 20, 2026, 4:30 PM EDT · 8 months ago Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)
Mar 16, 2026, 7:30 AM EDT · 8 months ago Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million
Mar 2, 2026, 7:30 AM EST · 8 months ago Zevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call
Feb 25, 2026, 7:30 AM EST · 8 months ago Zevra Therapeutics to Present at the Citizens Life Sciences Conference
Feb 24, 2026, 3:42 PM EST · 8 months ago Transpire Bio Strengthens its Leadership Team with Appointment of LaDuane Clifton as Chief Financial Officer
Feb 19, 2026, 10:38 AM EST · 9 months ago Zevra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Feb 4, 2026, 7:30 AM EST · 9 months ago Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™
Feb 2, 2026, 7:30 AM EST · 9 months ago Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026
Jan 26, 2026, 7:30 AM EST · 9 months ago Zevra Therapeutics to Present Multiple Analyses on MIPLYFFA® at the 22nd Annual WORLDSymposium™
Dec 2, 2025, 7:30 AM EST · 11 months ago Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD
Nov 5, 2025, 4:05 PM EST · 1 year ago Zevra Reports Third Quarter 2025 Financial Results and Corporate Update
Oct 29, 2025, 7:30 AM EDT · 1 year ago Zevra Therapeutics to Participate in the Guggenheim Healthcare Innovation Conference
Oct 27, 2025, 7:30 AM EDT · 1 year ago Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call
Sep 18, 2025, 7:30 AM EDT · 1 year ago Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA® (arimoclomol) and OLPRUVA® (sodium phenylbutyrate)
Sep 4, 2025, 7:30 AM EDT · 1 year ago Zevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA® (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM)
Aug 28, 2025, 7:30 AM EDT · 1 year ago Zevra Therapeutics Announces Multiple Datasets on MIPLYFFA® (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM)
Aug 26, 2025, 7:30 AM EDT · 1 year ago Zevra Therapeutics to Participate at Upcoming Investor Conferences in September
Aug 12, 2025, 4:05 PM EDT · 1 year ago Zevra Reports Second Quarter 2025 Financial Results and Corporate Update
Aug 4, 2025, 7:30 AM EDT · 1 year ago Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call
Jul 28, 2025, 6:00 AM EDT · 1 year ago Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C
Jul 18, 2025, 7:30 AM EDT · 1 year ago Zevra Therapeutics Announces MIPLYFFA® and OLPRUVA® Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG)
Jul 16, 2025, 7:30 AM EDT · 1 year ago Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism
May 29, 2025, 4:35 PM EDT · 1 year ago Zevra Announces Final Results of 2025 Annual Meeting of Stockholders
May 21, 2025, 7:30 AM EDT · 1 year ago All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company's Director Nominees
May 6, 2025, 7:30 AM EDT · 1 year ago Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call
Apr 17, 2025, 7:30 AM EDT · 1 year ago Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism